Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Roya Garakani

Ophthalmology Fort Lauderdale, FL Medical Doctor

NPI 1740818574 CMS profile 11300773

1600 S Andrews Ave, Fort Lauderdale, FL 33316

Open in the dashboard

General payments

$6,250

60 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roya Garakani of Fort Lauderdale, FL is reported in the CMS Open Payments database as having received $6,250 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,241 22
2024 General $2,163 30
2023 General $642 5
2022 General $181 2
2021 General $25 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roya Garakani
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Roya Garakani were reported at $3,241. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Roya Garakani Ophthalmology median Middle half National median
2019 $0 $258 $104–$655 $163
2020 $0 $126 $45–$321 $114
2021 $25 $205 $76–$534 $132
2022 $181 $266 $100–$678 $149
2023 $642 $308 $117–$745 $160
2024 $2,163 $340 $127–$846 $164
2025 $3,241 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Bausch & Lomb Americas Inc. $1,637 9 payments
  2. Glaukos Corporation $1,454 12 payments
  3. New World Medical,Inc. $1,336 18 payments
  4. Alcon Vision LLC $1,149 12 payments
  5. Sight Sciences, Inc. $312 4 payments
  6. AbbVie, Inc. $189 2 payments
  7. GlaxoSmithKline, LLC. $122 1 payment
  8. Dutch Ophthalmic, USA $26 1 payment
  9. Aerie Pharmaceuticals, Inc. $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,093 56 payments
  2. Travel and Lodging $1,295 3 payments
  3. Consulting Fee $863 1 payment
Products named General payments · program years 2021–2025
  1. Kahook Dual Blade $1,336 18 payments
  2. Clearpath $1,336 18 payments
  3. Ahmed Glaucoma Valve $1,336 18 payments
  4. Streamline $1,336 18 payments
  5. HYDRUS Microstent $612 6 payments
  6. iStent Trabecular Micro-Bypass System Model iS3 $427 7 payments
  7. Via360 $349 5 payments
  8. OMNI SURGICAL SYSTEM $312 4 payments
  9. Clareon $311 3 payments
  10. SION SURGICAL INSTRUMENT $133 2 payments
  11. Other $1,169 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

936

Median for Ophthalmology: 891

Drug cost

$26,383

Median for Ophthalmology: $68,233

Branded share of claims

23%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 11 $6,202
Prednisolone Acetate Generic 115 $4,693
Latanoprost Generic 263 $2,908
Ketorolac Tromethamine Generic 57 $2,534
Dorzolamide-Timolol Dorzolamide/Timolol/Pf Brand 11 $1,664
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 12 $1,458
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 98 $1,431
Brimonidine Tartrate Generic 88 $1,211
Dorzolamide Hcl Generic 62 $1,030
Travoprost Generic 11 $808

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$5,815

Medicare's payments for the services billed

Medicare patients

75

Average age 77

Services billed

105

41 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 32%
Depression 28%
Diabetes 27%
Chronic kidney disease 23%
Osteoporosis 19%
Atrial fibrillation 16%
Ischemic heart disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record